Literature DB >> 24461293

Dual inhibition of HCV and HIV by ring-expanded nucleosides containing the 5:7-fused imidazo[4,5-e][1,3]diazepine ring system. In vitro results and implications.

Ning Zhang1, Peng Zhang1, Andrea Baier2, Lucyna Cova3, Ramachandra S Hosmane4.   

Abstract

Examples of ring-expanded nucleosides (RENs), represented by general structures 1 and 2, exhibited dual anti-HCV and anti-HIV activities in both cell culture systems and the respective target enzyme assays, including HCV NTPase/helicase and human RNA helicase DDX3. Since HCV is a leading co-infection in late stage HIV AIDS patients, often leading to liver cirrhosis and death, the observed dual inhibition of HCV and HIV by the target nucleoside analogues has potentially beneficial implications in treating HIV patients infected with HCV.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiviral compounds; Dual inhibitors of HCV and HIV; Hepatitis C virus (HCV); Human immunodeficiency virus (HIV); Imidazo[4,5-e][1,3]diazepines; In vitro screening; Inhibition of HCV NTPase/helicase; Inhibition of RNA helicase DDX3; Organic synthesis; Ring-expanded nucleosides

Mesh:

Substances:

Year:  2014        PMID: 24461293      PMCID: PMC3979313          DOI: 10.1016/j.bmcl.2013.12.121

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  29 in total

Review 1.  Critical issues of HIV treatment in the era of highly active antiretroviral therapy.

Authors:  M Battegay
Journal:  Expert Opin Investig Drugs       Date:  2001-02       Impact factor: 6.206

Review 2.  Impact of HIV infection and antiretroviral therapy in the older patient.

Authors:  Roberto Manfredi
Journal:  Expert Rev Anti Infect Ther       Date:  2004-12       Impact factor: 5.091

3.  Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease.

Authors:  Nicolás Merchante; José A Girón-González; Mercedes González-Serrano; Julian Torre-Cisneros; José A García-García; Ana Arizcorreta; Josefa Ruiz-Morales; Pilar Cano-Lliteras; Fernando Lozano; Carmen Martínez-Sierra; Juan Macías; Juan A Pineda
Journal:  AIDS       Date:  2006-01-02       Impact factor: 4.177

4.  Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.

Authors:  Victor E Buckwold; Jiayi Wei; Zhuhui Huang; Chunsheng Huang; Aysegul Nalca; Jay Wells; Julie Russell; Barbara Collins; Roger Ptak; William Lang; Curtis Scribner; Dennis Blanchett; Tom Alessi; Peter Langecker
Journal:  Antiviral Res       Date:  2006-09-11       Impact factor: 5.970

5.  Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding.

Authors:  J L Kim; K A Morgenstern; J P Griffith; M D Dwyer; J A Thomson; M A Murcko; C Lin; P R Caron
Journal:  Structure       Date:  1998-01-15       Impact factor: 5.006

6.  Can HCV affect the efficacy of anti-HIV treatment?

Authors:  P Filippini; N Coppola; C Scolastico; G Liorre; R Nocera; E Sagnelli; F Piccinino
Journal:  Arch Virol       Date:  2000       Impact factor: 2.574

7.  Liver histopathology in human immunodeficiency virus-hepatitis C virus co-infected patients with fatal liver disease.

Authors:  Mathias Lichterfeld; Susanne Haas; Hans-Peter Fischer; Ester Voigt; Jürgen K Rockstroh; Ulrich Spengler
Journal:  J Gastroenterol Hepatol       Date:  2005-05       Impact factor: 4.029

8.  Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.

Authors:  Juan Macías; Victor Castellano; Nicolás Merchante; Rosa B Palacios; José A Mira; Carmen Sáez; José A García-García; Fernando Lozano; Jesús M Gómez-Mateos; Juan A Pineda
Journal:  AIDS       Date:  2004-03-26       Impact factor: 4.177

9.  Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus.

Authors:  P Gallinari; D Brennan; C Nardi; M Brunetti; L Tomei; C Steinkühler; R De Francesco
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

10.  Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus.

Authors:  Ning Zhang; Huan-Ming Chen; Verena Koch; Herbert Schmitz; Ching-Len Liao; Maria Bretner; Vishweshwar S Bhadti; Ali I Fattom; Robert B Naso; Ramachandra S Hosmane; Peter Borowski
Journal:  J Med Chem       Date:  2003-09-11       Impact factor: 7.446

View more
  3 in total

Review 1.  DDX3X structural analysis: Implications in the pharmacology and innate immunity.

Authors:  Luigi De Colibus; Melissa Stunnenberg; Teunis B H Geijtenbeek
Journal:  Curr Res Immunol       Date:  2022-05-24

2.  Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents.

Authors:  Annalaura Brai; Roberta Fazi; Cristina Tintori; Claudio Zamperini; Francesca Bugli; Maurizio Sanguinetti; Egidio Stigliano; José Esté; Roger Badia; Sandra Franco; Miguel A Martinez; Javier P Martinez; Andreas Meyerhans; Francesco Saladini; Maurizio Zazzi; Anna Garbelli; Giovanni Maga; Maurizio Botta
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-26       Impact factor: 11.205

Review 3.  DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs.

Authors:  Marina K Kukhanova; Inna L Karpenko; Alexander V Ivanov
Journal:  Molecules       Date:  2020-02-24       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.